SEARCH

SEARCH BY CITATION

References

  • Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF et al. (2007). Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109: 30313041.
  • Akin C (2006). Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8: 412419.
  • Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. (2003). Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686692.
  • Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004). A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103: 32223225.
  • Akin C, Metcalfe DD (2004). The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114: 1319.
  • Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al. (2007). Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with ‘idiopathic’ anaphylaxis. Blood 110: 23312333.
  • Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q (2004). The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy 34: 911916.
  • Alexeev V, Yoon K (2006). Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126: 11021110.
  • Ando A, Martin TR, Galli SJ (1993). Effects of chronic treatment with the c-kit ligand, stem cell factor, on immunoglobulin E-dependent anaphylaxis in mice. Genetically mast cell-deficient Sl/Sld mice acquire anaphylactic responsiveness, but the congenic normal mice do not exhibit augmented responses. J Clin Invest 92: 16391649.
  • Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P (2004). Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem 279: 1224912259.
  • Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. (2000). C-kit mutations in core binding factor leukemias. Blood 95: 726727.
  • Broudy VC (1997). Stem cell factor and hematopoiesis. Blood 90: 13451364.
  • Broudy VC, Kovach NL, Bennett LG, Lin N, Jacobsen FW, Kidd PG (1994). Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83: 21452152.
  • Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D et al. (2007). The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines. Leuk Lymphoma 48: 13791388.
  • Chow LQ, Eckhardt SG (2007). Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884896.
  • Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL et al. (2004). Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104: 37543757.
  • Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA et al. (1996). Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183: 26812686.
  • Dastych J, Metcalfe DD (1994). Stem cell factor induces mast cell adhesion to fibronectin. J Immunol 152: 213219.
  • Dastych J, Taub D, Hardison MC, Metcalfe DD (1998). Tyrosine kinase-deficient Wv c-kit induces mast cell adhesion and chemotaxis. Am J Physiol 275: C1291C1299.
  • Dorsey JF, Jove R, Kraker AJ, Wu J (2000). The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 31273131.
  • Droogendijk HJ, Kluin-Nelemans HJ, Van Doormaal JJ, Oranje AP, Van De Loosdrecht AA, Van Daele PL (2006). Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107: 345351.
  • Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A et al. (2000). PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15: 1728.
  • Flanagan JG, Leder P (1990). The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63: 185194.
  • Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K et al. (2005). Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 136: 273280.
  • Fogel WA, Lewinski A, Jochem J (2005). Histamine in idiopathic inflammatory bowel diseases—not a standby player. Folia Med Cracov 46: 107118.
  • Fumo G, Akin C, Metcalfe DD, Neckers L (2004). 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103: 10781084.
  • Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. (1993). Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 17361744.
  • Gabillot-Carre M, Lepelletier Y, Humbert M, De Sepuvelda P, Hamouda NB, Zappulla JP et al. (2006). Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108: 10651072.
  • Galli SJ, Nakae S, Tsai M (2005). Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135142.
  • Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. (2006). KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108: 23662372.
  • Gilfillan AM, Tkaczyk C (2006). Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6: 218230.
  • Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. (2006). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107: 752759.
  • Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. (2007). Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92: 14511459.
  • Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106: 28652870.
  • Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C et al. (2007). The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a Phase II trial. Blood 110: 1035a.
  • Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. (2007). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104: 1328313288.
  • Heinemann A, Sturm GJ, Ofner M, Sturm EM, Weller C, Peskar BA et al. (2005). Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils. J Allergy Clin Immunol 116: 820826.
  • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925932.
  • Herbst R, Shearman MS, Jallal B, Schlessinger J, Ullrich A (1995). Formation of signal transfer complexes between stem cell and platelet-derived growth factor receptors and SH2 domain proteins in vitro. Biochemistry 34: 59715979.
  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577580.
  • Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP et al. (2006). A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis. Blood 108: 764a.
  • Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC (2004). Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res 120: 288294.
  • Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y et al. (2000). Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60: 23452347.
  • Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW et al. (1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63: 225233.
  • Iwaki S, Tkaczyk C, Satterthwaite AB, Halcomb K, Beaven MA, Metcalfe DD et al. (2005). Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit. J Biol Chem 280: 4026140270.
  • Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM (2008). Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther 324: 128138.
  • Jensen BM, Metcalfe DD, Gilfillan AM (2007). Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. Inflamm Allergy Drug Targets 6: 5762.
  • Juurikivi A, Sandler C, Lindstedt KA, Kovanen PT, Juutilainen T, Leskinen MJ et al. (2005). Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 64: 11261131.
  • Kapur R, Majumdar M, Xiao X, Ndrews-Hill M, Schindler K, Williams DA (1998). Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood 91: 879889.
  • Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM (2008). Activation and function of the mTORC1 pathway in mast cells. J Immunol 180: 45864595.
  • Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999). Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94: 23332342.
  • Kitamura Y, Go S (1979). Decreased production of mast cells in S1/S1d anemic mice. Blood 53: 492497.
  • Kitamura Y, Go S, Hatanaka K (1978). Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52: 447452.
  • Kitamura Y, Oboki K, Ito A (2006). Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am 26: 387405.
  • Kitamura Y, Tsujimura T, Jippo T, Kasugai T, Kanakura Y (1995). Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol 107: 5456.
  • Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H et al. (1995). Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790798.
  • Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J et al. (1996). Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88: 9951004.
  • Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. (2003). Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101: 46604666.
  • Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. (2004). Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473478.
  • Kojima S, Matsuyama T, Kodera Y (1997). Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br J Haematol 99: 440446.
  • Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F (2007). Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 26: 39043908.
  • Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA (1998). SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 18: 20892099.
  • Kuehn HS, Gilfillan AM (2007). G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett 113: 5969.
  • Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC et al. (2008). Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93: 4956.
  • Lawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A et al. (2005). Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res 572: 113.
  • Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R (2005). Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23: 1643.
  • Lev S, Givol D, Yarden Y (1992). Interkinase domain of kit contains the binding site for phosphatidylinositol 3′ kinase. Proc Natl Acad Sci USA 89: 678682.
  • Levitzki A, Mishani E (2006). Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75: 93109.
  • Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM (2007). Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130: 166176.
  • Linnekin D (1999). Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31: 10531074.
  • Linnekin D, DeBerry CS, Mou S (1997). Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 272: 2745027455.
  • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 1185111858.
  • Lober K, Alfonso A, Escribano L, Botana LM (2008). STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. J Cell Biochem 103: 865876.
  • Lorentz A, Schuppan D, Gebert A, Manns MP, Bischoff SC (2002). Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood 99: 966972.
  • Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. (2002). The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99: 17411744.
  • Malone DG, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD (1986). Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum 29: 956963.
  • Malone DG, Metcalfe DD (1988). Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific IgE and parenteral challenge with specific antigen. Arthritis Rheum 31: 10631067.
  • Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD (1987). Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum 30: 130137.
  • Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T et al. (2007). KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 120: 680687.
  • Metcalfe DD, Baram D, Mekori YA (1997). Mast cells. Physiol Rev 77: 10331079.
  • Metcalfe DD, Mekori JA, Rottem M (1995). Mast cell ontogeny and apoptosis. Exp Dermatol 4: 227230.
  • Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 3165531663.
  • Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC et al. (2003). Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 278: 3146131464.
  • Muto S, Katsuki M, Horie S (2007). Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Sci 98: 15491556.
  • Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. (1995). Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92: 1056010564.
  • Nilsson G, Butterfield JH, Nilsson K, Siegbahn A (1994). Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153: 37173723.
  • Okayama Y, Kawakami T (2006). Development, migration, and survival of mast cells. Immunol Res 34: 97115.
  • Oshitani N, Kamata N, Inagawa M, Yamagami H, Watanabe K, Fujiwara Y et al. (2006). Significance of activated mast cells in submucosa and muscularis propria of patients with Crohn's disease detected by a novel anti-mast cell surface molecule antibody. Aliment Pharmacol Ther 24: 14.
  • Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. (2007). EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 109: 315322.
  • Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. (2003a). Imatinib for systemic mast-cell disease. Lancet 362: 535536.
  • Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. (2003b). CHIC2 deletion, a surrogate for FIP1L1–PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102: 30933096.
  • Pardanani A, Reeder T, Li CY, Tefferi A (2003c). Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 27: 883885.
  • Patnaik MM, Tefferi A, Pardanani A (2007). Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 7: 492503.
  • Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P et al. (2006). Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 26222627.
  • Price DJ, Rivnay B, Fu Y, Jiang S, Avraham S, Avraham H (1997). Direct association of Csk homologous kinase (CHK) with the diphosphorylated site Tyr568/570 of the activated c-KIT in megakaryocytes. J Biol Chem 272: 59155920.
  • Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG et al. (2005). Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 33853391.
  • Reber L, Da Silva CA, Frossard N (2006). Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533: 327340.
  • Rivera J, Gilfillan AM (2006). Molecular regulation of mast cell activation. J Allergy Clin Immunol 117: 12141225.
  • Roskoski Jr R (2005a). Signaling by Kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 337: 113.
  • Roskoski Jr R (2005b). Structure and regulation of Kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 338: 13071315.
  • Samayawardhena LA, Hu J, Stein PL, Craig AW (2006). Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Cell Signal 18: 14471454.
  • Scheinfeld N (2006). A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol 5: 117122.
  • Schirmer A, Kennedy J, Murli S, Reid R, Santi DV (2006). Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA 103: 42344239.
  • Serve H, Hsu YC, Besmer P (1994). Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269: 60266030.
  • Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C (2006). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286291.
  • Shivakrupa R, Linnekin D (2005). Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. Cell Signal 17: 103109.
  • Sonpavde G, Hutson TE (2007). Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9: 115119.
  • Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P et al. (2007). Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13: 719724.
  • Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. (2005). A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 23242331.
  • Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C et al. (2001). The Kit-activating mutation D816V enhances stem cell factor—dependent chemotaxis. Blood 98: 11951199.
  • Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG et al. (2004). Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 6: 335342.
  • Theoharides TC, Conti P (2004). Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 25: 235241.
  • Theoharides TC, Kempuraj D, Iliopoulou BP (2007). Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 601: 423430.
  • Thommes K, Lennartsson J, Carlberg M, Ronnstrand L (1999). Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem J 341 (Part 1): 211216.
  • Tian Q, Frierson Jr HF, Krystal GW, Moskaluk CA (1999). Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154: 16431647.
  • Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson LE, Satterthwaite AB et al. (2004). NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood 104: 207214.
  • Tkaczyk C, Jensen BM, Iwaki S, Gilfillan AM (2006). Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy Clin North Am 26: 427450.
  • Toksoz D, Zsebo KM, Smith KA, Hu S, Brankow D, Suggs SV et al. (1992). Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 89: 73507354.
  • Trieselmann NZ, Soboloff J, Berger SA (2003). Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 60: 759766.
  • Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. (2003a). Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27: 635641.
  • Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. (2003b). Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122: 695717.
  • Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. (2001). Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603625.
  • Van Dijk TB, Van Den Akker E, Amelsvoort MP, Mano H, Lowenberg B, Von Lindern M (2000). Stem cell factor induces phosphatidylinositol 3′-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood 96: 34063413.
  • Vendome J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C et al. (2005). Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 48: 61946201.
  • Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P et al. (2006a). Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30: 13651370.
  • Verstovsek S, Kantarjian H, Cortes J, Ravandi-Kashani F, Borthakur G, Nicaise C et al. (2006b). Dasatinib (Sprycel (TM)) therapy for patients with systemic mastocytosis. Blood 108: 1036a.
  • Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ et al. (1987). Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 33413351.
  • Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA (1997). Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 186: 313323.
  • Zappulla JP, Dubreuil P, Desbois S, Letard S, Hamouda NB, Daeron M et al. (2005). Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 202: 16351641.
  • Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N et al. (2003). Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22: 660664.